Literature DB >> 33503061

Increased risk of falls and fractures in patients with psychosis and Parkinson disease.

Joan Forns1, J Bradley Layton2, Jennifer Bartsch3, Mary Ellen Turner4, Colleen Dempsey4, Mary Anthony2, Mary E Ritchey2, George Demos4.   

Abstract

OBJECTIVE: Evaluate whether the risk of falls and fractures differs between patients with Parkinson disease with psychosis (PDP) and patients with Parkinson disease (PD) without psychosis at similar disease stages.
METHODS: Patients with PD without psychosis were identified in the Medicare claims databases (2008-2018) and followed from the first PD diagnosis date during the study period. Patients with a subsequent diagnosis of psychosis were included in the PDP group. Patients with PDP and PD without psychosis were propensity score-matched based on characteristics within blocks of time since cohort entry. The incidence rates (IRs), expressed per 100 person-years, and 95% confidence intervals (CIs) of falls and fractures were evaluated as composite and separate outcomes. Incidence rate ratios (IRRs) were used to compare patients with PDP and PD without psychosis in the matched cohort.
RESULTS: 154,306 patients had PD without psychosis and no falls or fractures before cohort entry; the IR for falls and fractures was 11.41 events (95% CI, 11.29-11.53). 12,127 patients (7.8%) had a subsequent PDP diagnosis. PDP patients had a higher prevalence of most comorbidities and risk factors for falls and fractures than those without psychosis. The crude IR for falls and fractures among PDP patients was 29.03 events (95% CI, 28.27-29.81). PD without psychosis and PDP groups had more falls than fractures. After matching, 24,144 PD patients without psychosis (15.6%) and 12,077 PDP patients (99.6%) were retained. Matched PDP patients had a higher incidence of falls and fractures than PD patients without psychosis (IRR = 1.44; 95% CI, 1.39-1.49). The higher increased rate was noted separately for falls (IRR = 1.48; 95% CI, 1.43-1.54) and any fractures (IRR = 1.17; 95% CI, 1.08-1.27) as well as within specific types of fracture, including pelvis and hip fractures.
CONCLUSIONS: Our findings suggest a modest but consistently higher increased risk of falls and fractures in PDP patients compared with PD patients without psychosis.

Entities:  

Year:  2021        PMID: 33503061      PMCID: PMC7840029          DOI: 10.1371/journal.pone.0246121

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  16 in total

Review 1.  Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.

Authors:  Doral Fredericks; James C Norton; Carolyn Atchison; Robert Schoenhaus; Michael W Pill
Journal:  Am J Manag Care       Date:  2017-04       Impact factor: 2.229

2.  Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults: Validation of an Existing Medicare Claims-based Algorithm.

Authors:  Carmen C Cuthbertson; Anna Kucharska-Newton; Keturah R Faurot; Til Stürmer; Michele Jonsson Funk; Priya Palta; B Gwen Windham; Sydney Thai; Jennifer L Lund
Journal:  Epidemiology       Date:  2018-07       Impact factor: 4.822

3.  An observational study of antipsychotic medication use among long-stay nursing home residents without qualifying diagnoses.

Authors:  Lorraine J Phillips; Nancy M Birtley; Gregory F Petroski; Carol Siem; Marilyn Rantz
Journal:  J Psychiatr Ment Health Nurs       Date:  2018-08-02       Impact factor: 2.952

Review 4.  Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.

Authors:  Yasaman Kianirad; Tanya Simuni
Journal:  Expert Rev Clin Pharmacol       Date:  2017-10-17       Impact factor: 5.045

Review 5.  Psychosis in Parkinson's disease: identification, prevention and treatment.

Authors:  Johannes Levin; Alkomiet Hasan; Günter U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2015-04-18       Impact factor: 3.575

6.  Fracture risk associated with parkinsonism and anti-Parkinson drugs.

Authors:  Peter Vestergaard; Lars Rejnmark; Leif Mosekilde
Journal:  Calcif Tissue Int       Date:  2007-08-20       Impact factor: 4.333

7.  Off-label use of antipsychotic medications in Medicaid.

Authors:  Douglass L Leslie; Robert Rosenheck
Journal:  Am J Manag Care       Date:  2012-03-01       Impact factor: 2.229

8.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

9.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373

Review 10.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Authors:  Raquel N Taddei; Seyda Cankaya; Sandeep Dhaliwal; K Ray Chaudhuri
Journal:  Parkinsons Dis       Date:  2017-09-12
View more
  2 in total

1.  Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.

Authors:  J Bradley Layton; Joan Forns; Mary Ellen Turner; Colleen Dempsey; Jennifer L Bartsch; Mary S Anthony; Heather E Danysh; Mary E Ritchey; George Demos
Journal:  Drugs Real World Outcomes       Date:  2021-10-30

Review 2.  Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms.

Authors:  Shuo Zhang; Yan Ma
Journal:  World J Psychiatry       Date:  2022-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.